newly diagnosed amyloid light chain amyloidosis research hub

A Phase 2, open-label, randomized, dose optimization study evaluating the efficacy and safety of belantamab mafodotin administered in combination with cyclophosphamide, bortezomib, and dexamethasone in adult participants with newly diagnosed amyloid light chain amyloidosis (ALANIS)

This study is testing a new drug combination for people newly diagnosed with AL amyloidosis. Researchers want to see if adding a targeted medicine called belantamab mafodotin to standard treatments helps clear abnormal proteins from the blood, improves organ health, and works safely at the right dose.